-1750794499192.webp&w=3840&q=75)
2025 MLS Nashville | Renal Cell Cancer Updates in 2025
Overview
Dr. Tan reported that adjuvant pembrolizumab delivered a 61 % five‑year DFS and a 5.5 % OS gain in high‑risk clear‑cell RCC (KEYNOTE‑564), while ipilimumab + nivolumab sustained a 31 % nine‑year OS in metastatic disease (CheckMate 214). Subsequent approaches showed mixed results: nivolumab‑cabozantinib in PEDIGREE incurred notable grade‑5 toxicity, casdatinib‑cabozantinib in ARC‑20 achieved a 46 % ORR, and an early CAR‑T therapy for clear‑cell RCC produced a 31 % confirmed response.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Alan Tan, MD
Date of Release
June 25th, 2025
